by mediaid pharmacy | Jan 24, 2026 | Blogs
Afanix 40 mg (Afatinib) is an advanced targeted cancer therapy widely prescribed for the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. Manufactured under strict pharmaceutical standards, Afanix Tablet 40 mg belongs to the class of...
by mediaid pharmacy | Jan 24, 2026 | Blogs
Ibrutix 140 mg is a targeted oral cancer medication containing Ibrutinib, widely prescribed for several blood-related malignancies. It belongs to the class of Bruton’s Tyrosine Kinase (BTK) inhibitors, offering precision-based therapy with proven clinical outcomes....
by mediaid pharmacy | Jan 22, 2026 | Blogs
Ponatinix 15 mg (Ponatinib) is a third-generation tyrosine kinase inhibitor (TKI) widely prescribed in oncology for resistant or relapsed chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). What Is Ponatinix 15...
by mediaid pharmacy | Jan 22, 2026 | Blogs
Osimertinib (Tagrix) 40mg & 80mg is a next-generation targeted therapy widely prescribed in oncology for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). As a third-generation EGFR tyrosine kinase inhibitor (TKI), Osimertinib is clinically proven...
by mediaid pharmacy | Jan 21, 2026 | Blogs
Olanib 50 mg is an oral anti-cancer medicine containing Olaparib INN, a PARP inhibitor widely used in targeted oncology therapy. It is prescribed mainly for BRCA-mutated cancers and selected solid tumors under specialist supervision. What Is Olanib Tablet 50mg? Olanib...
by mediaid pharmacy | Jan 17, 2026 | Blogs
Cancer treatment decisions are rarely simple especially when patients and caregivers are navigating complex diagnoses like ovarian or breast cancer. Alongside emotional stress, there’s often confusion around which medicines work best, how targeted therapies differ...
